Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?
Thomas Wilke,1 Sabrina Mueller,2 Sabine Bauer,2 Silvia Pitura,3 Leona Probst,3 Boris A Ratsch,3 Hans Salwender4 1Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), 23966 Wismar, Germany; 2Ingress-Health, 23966 Wismar, Germany; 3Takeda Pharma Vertrieb GmbH & Co....
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-11-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/treatment-of-relapsed-refractory-multiple-myeloma-which-new-pi-based-c-peer-reviewed-article-PPA |
| _version_ | 1819085440326565888 |
|---|---|
| author | Wilke T Mueller S Bauer S Pitura S Probst L Ratsch BA Salwender H |
| author_facet | Wilke T Mueller S Bauer S Pitura S Probst L Ratsch BA Salwender H |
| author_sort | Wilke T |
| collection | DOAJ |
| description | Thomas Wilke,1 Sabrina Mueller,2 Sabine Bauer,2 Silvia Pitura,3 Leona Probst,3 Boris A Ratsch,3 Hans Salwender4 1Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), 23966 Wismar, Germany; 2Ingress-Health, 23966 Wismar, Germany; 3Takeda Pharma Vertrieb GmbH & Co. KG, 10117 Berlin, Germany; 4Asklepios Kliniken Hamburg GmbH, 22763 Hamburg, Germany Background and objectives: This study describes preferences of German relapsed refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based combination treatments.Methods: Patients with a minimum age of 18 years and a diagnosis of RRMM were included. Their preferences were assessed using a discrete choice experiment design, which was developed based on a literature review and two patient focus group discussions. The final discrete choice experiment design consisted of four attributes, namely “therapy application regimen,” “time without progression of disease,” “possibility of grade ≥3 adverse events (AEs) affecting the blood,” and “possibility of grade ≥3 AE heart failure.”Results: Analysis was based on 84 patients (36.9% females, mean age 62.7 years, mean multiple myeloma disease duration 5.5 years). Among the tested attributes, “therapy application regimen” was assigned the highest importance for treatment decisions (38.8%), the second important attribute was “time without progression of disease” (38.7%), followed by “possibility of AE heart failure” (13.9%) and “possibility of AEs affecting the blood” (8.6%). Patients preferred oral intake once a day and once a week over other application modes such as oral intake once a day and once a week plus twice-weekly infusions. Furthermore, they preferred longer disease progression-free time and lower risk of grade ≥3 AEs. The highest overall utility was derived for ixazomib + lenalidomide + dexamethasone (utility: 3.218), compared with lenalidomide + dexamethasone (2.769), and carfilzomib + lenalidomide + dexamethasone (1.928).Conclusion: RRMM patients prefer treatments with an all-oral application, a longer disease-progression-free time, and a lower probability of AEs. If patients face tradeoffs, they accept a lower progression-free time and/or higher AE rates to get an all-oral therapy. Keywords: MM patient’s treatment preferences, relapsed refractory multiple myeloma, RRMM, discrete choice experiment, DCE |
| first_indexed | 2024-12-21T21:04:23Z |
| format | Article |
| id | doaj.art-bf6d131b2f5f48299ff4a3746c2602ea |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-21T21:04:23Z |
| publishDate | 2018-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-bf6d131b2f5f48299ff4a3746c2602ea2022-12-21T18:50:21ZengDove Medical PressPatient Preference and Adherence1177-889X2018-11-01Volume 122387239642212Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?Wilke TMueller SBauer SPitura SProbst LRatsch BASalwender HThomas Wilke,1 Sabrina Mueller,2 Sabine Bauer,2 Silvia Pitura,3 Leona Probst,3 Boris A Ratsch,3 Hans Salwender4 1Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), 23966 Wismar, Germany; 2Ingress-Health, 23966 Wismar, Germany; 3Takeda Pharma Vertrieb GmbH & Co. KG, 10117 Berlin, Germany; 4Asklepios Kliniken Hamburg GmbH, 22763 Hamburg, Germany Background and objectives: This study describes preferences of German relapsed refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based combination treatments.Methods: Patients with a minimum age of 18 years and a diagnosis of RRMM were included. Their preferences were assessed using a discrete choice experiment design, which was developed based on a literature review and two patient focus group discussions. The final discrete choice experiment design consisted of four attributes, namely “therapy application regimen,” “time without progression of disease,” “possibility of grade ≥3 adverse events (AEs) affecting the blood,” and “possibility of grade ≥3 AE heart failure.”Results: Analysis was based on 84 patients (36.9% females, mean age 62.7 years, mean multiple myeloma disease duration 5.5 years). Among the tested attributes, “therapy application regimen” was assigned the highest importance for treatment decisions (38.8%), the second important attribute was “time without progression of disease” (38.7%), followed by “possibility of AE heart failure” (13.9%) and “possibility of AEs affecting the blood” (8.6%). Patients preferred oral intake once a day and once a week over other application modes such as oral intake once a day and once a week plus twice-weekly infusions. Furthermore, they preferred longer disease progression-free time and lower risk of grade ≥3 AEs. The highest overall utility was derived for ixazomib + lenalidomide + dexamethasone (utility: 3.218), compared with lenalidomide + dexamethasone (2.769), and carfilzomib + lenalidomide + dexamethasone (1.928).Conclusion: RRMM patients prefer treatments with an all-oral application, a longer disease-progression-free time, and a lower probability of AEs. If patients face tradeoffs, they accept a lower progression-free time and/or higher AE rates to get an all-oral therapy. Keywords: MM patient’s treatment preferences, relapsed refractory multiple myeloma, RRMM, discrete choice experiment, DCEhttps://www.dovepress.com/treatment-of-relapsed-refractory-multiple-myeloma-which-new-pi-based-c-peer-reviewed-article-PPAMM patient’s treatment preferencesrelapsed refractory multiple myeloma (RRMM)discrete choice experimentDCE |
| spellingShingle | Wilke T Mueller S Bauer S Pitura S Probst L Ratsch BA Salwender H Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? Patient Preference and Adherence MM patient’s treatment preferences relapsed refractory multiple myeloma (RRMM) discrete choice experiment DCE |
| title | Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? |
| title_full | Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? |
| title_fullStr | Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? |
| title_full_unstemmed | Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? |
| title_short | Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? |
| title_sort | treatment of relapsed refractory multiple myeloma which new pi based combination treatments do patients prefer |
| topic | MM patient’s treatment preferences relapsed refractory multiple myeloma (RRMM) discrete choice experiment DCE |
| url | https://www.dovepress.com/treatment-of-relapsed-refractory-multiple-myeloma-which-new-pi-based-c-peer-reviewed-article-PPA |
| work_keys_str_mv | AT wilket treatmentofrelapsedrefractorymultiplemyelomawhichnewpibasedcombinationtreatmentsdopatientsprefer AT muellers treatmentofrelapsedrefractorymultiplemyelomawhichnewpibasedcombinationtreatmentsdopatientsprefer AT bauers treatmentofrelapsedrefractorymultiplemyelomawhichnewpibasedcombinationtreatmentsdopatientsprefer AT pituras treatmentofrelapsedrefractorymultiplemyelomawhichnewpibasedcombinationtreatmentsdopatientsprefer AT probstl treatmentofrelapsedrefractorymultiplemyelomawhichnewpibasedcombinationtreatmentsdopatientsprefer AT ratschba treatmentofrelapsedrefractorymultiplemyelomawhichnewpibasedcombinationtreatmentsdopatientsprefer AT salwenderh treatmentofrelapsedrefractorymultiplemyelomawhichnewpibasedcombinationtreatmentsdopatientsprefer |